Colorectal Cancer Treatments and Studies

This study identifies interferon signaling in epithelial cells as a factor contributing to incomplete response to chemotherapy in colorectal cancer, suggesting potential therapeutic targets.

This study develops a 37-gene prognostic signature for colon cancer and identifies a subgroup sensitive to tubulin inhibitors, with potential for drug repurposing.

The paper trains an ensemble classifier to predict cetuximab sensitivity in colorectal cancer PDXs using multi-omic data, achieving high accuracy and demonstrating its utility for therapeutic biomarker development.

The paper shows 5-FU induces translational reprogramming in colorectal cancer cells, enhancing drug tolerance through pro-tumoral gene expression and IL-8 overexpression.

This study identifies paclitaxel as a synergistic partner for trametinib in KRAS-mutated colorectal cancer, showing enhanced anti-tumor effects in vitro and in vivo.

The paper introduces a gene interaction perturbation network approach to classify colorectal cancer into six subtypes with distinct molecular and clinical features.

This study shows that goblet cell content influences CMS3 subtype classification in colorectal cancer using machine learning.

The paper identifies two molecular and clinically distinct subtypes within CMS2 and CMS4 of colorectal cancer using metastasis and cancer stem cell markers.

This paper reviews pharmacogenomics biomarkers and genomic alterations in colorectal cancer to improve precision medicine strategies, with a focus on Latin America.